Ludmila P. Evstigneeva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ludmila P. Evstigneeva has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Ol'Ga Mikhaylovna Lesnyak
Department of Family Medicine, North-Western State Medical University named after I.I. Mechnikov, St. Petersburg 195298, Russia
7 shared publications - Ekaterina Nailyevna Dudinskaya
Pirogov Russian National Research Medical University (Pirogov University)
4 shared publications - Elena N. Gladkova
North-Western State Medical University Named After I.I. Mechnikov
4 shared publications - Kseniia Yu. Belova
Yaroslavl State Medical University
4 shared publications - Maria I. Fominykh
Ural State Medical University
4 shared publications - Olga B. Ershova
Yaroslavl State Medical University
3 shared publications
Latest Publications
- Open Access
- 17 August 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (4) , 132-135
Resolution of the Expert Council “Reproductive health of patients with rheumatic diseases during targeted therapy: from preconception preparation to postpartum follow-up”
On June 19, 2026, a meeting of the Expert Council was held to discuss reproductive health issues in patients with immune-mediated inflammatory rheumatic diseases and the safety of antirheumatic therapy. Rheumatologists, obstetrician-gynecologists, reproductive medicine specialists, and other experts participated in the discussion.
- 17 August 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (4) , 132-135
Open AccessResolution of the Expert Council “Reproductive health of patients with rheumatic diseases during targeted therapy: from preconception preparation to postpartum follow-up”
On June 19, 2026, a meeting of the Expert Council was held to discuss reproductive health issues in patients with immune-mediated inflammatory rheumatic diseases and the safety of antirheumatic therapy. Rheumatologists, obstetrician-gynecologists, reproductive medicine specialists, and other experts participated in the discussion.
- 24 June 2026
- Published by Alfmed LLC in Medical alphabet
- No. 12
Assessment of rheumatoid arthritis activity and treatment with disease-modifying anti-rheumatic drugs in outpatients in routine clinical practice
Objective . To assess rheumatoid arthritis (RA) activity and the adequacy of ongoing conventional disease-modifying anti-rheumatic therapy in outpatients in real-world clinical practice. Materials and methods . A total of 115 outpatients with RA who consulted a rheumatologist were examined. Disease activity was assessed using the DAS 28-CRP index; the physician’s global assessment of activity, the ratio of tender to swollen joints, and the results of the HADS and FIRST questionnaires were also taken into account. The effectiveness of regular follow-up was analyzed. Results . According to DAS 28-CRP, remission/low disease activity was identified in 43.7 % of patients, moderate activity in 42.7 %, and high activity in 13.6 %. At the same time, objective signs of inflammatory activity (elevated CRP and ≥1 swollen joint) were observed in only 22.3 % of patients. In 34.0 % of patients, DAS 28 overestimated disease activity; this was associated with anxiety, depression, or fibromyalgia. Signs of at least one of these comorbid conditions were detected in 52.6 % of the patients examined. The effectiveness of regular follow-up was demonstrated: high RA activity was observed in 32.1 % of patients with irregular rheumatology visits, whereas among patients seen by a rheumatologist every 6 months or more frequently, high RA activity was recorded in 12.0 % (p=0.014). In 18.4 % of patients, the potential of basic therapy had not been fully exhausted. Conclusions . The DAS 28-CRP index may overestimate RA activity due to subjective factors; therefore, screening for anxiety, depression, and fibromyalgia appears advisable. Control of RA activity improves with regular patient follow-up, indicating the need to establish structured dispensary monitoring.
- 24 June 2026
- Published by Alfmed LLC in Medical alphabet
- No. 12
Assessment of rheumatoid arthritis activity and treatment with disease-modifying anti-rheumatic drugs in outpatients in routine clinical practice
Objective . To assess rheumatoid arthritis (RA) activity and the adequacy of ongoing conventional disease-modifying anti-rheumatic therapy in outpatients in real-world clinical practice. Materials and methods . A total of 115 outpatients with RA who consulted a rheumatologist were examined. Disease activity was assessed using the DAS 28-CRP index; the physician’s global assessment of activity, the ratio of tender to swollen joints, and the results of the HADS and FIRST questionnaires were also taken into account. The effectiveness of regular follow-up was analyzed. Results . According to DAS 28-CRP, remission/low disease activity was identified in 43.7 % of patients, moderate activity in 42.7 %, and high activity in 13.6 %. At the same time, objective signs of inflammatory activity (elevated CRP and ≥1 swollen joint) were observed in only 22.3 % of patients. In 34.0 % of patients, DAS 28 overestimated disease activity; this was associated with anxiety, depression, or fibromyalgia. Signs of at least one of these comorbid conditions were detected in 52.6 % of the patients examined. The effectiveness of regular follow-up was demonstrated: high RA activity was observed in 32.1 % of patients with irregular rheumatology visits, whereas among patients seen by a rheumatologist every 6 months or more frequently, high RA activity was recorded in 12.0 % (p=0.014). In 18.4 % of patients, the potential of basic therapy had not been fully exhausted. Conclusions . The DAS 28-CRP index may overestimate RA activity due to subjective factors; therefore, screening for anxiety, depression, and fibromyalgia appears advisable. Control of RA activity improves with regular patient follow-up, indicating the need to establish structured dispensary monitoring.
- 31 March 2026
- Published by Ryazan State Medical University in Nauka Molodykh (Eruditio Juvenium)
- Vol. 14 (1)
Characteristics of Patients with Secondary Osteoporotic Fractures: Risk Factors, Diagnosis, and Treatment According to PROMETHEUS Registry Data
BACKGROUND: Individuals who have suffered fragility fractures, deserve special attention. Diagnosis and treatment of such patients remain unsatisfactory. To address this issue, in 2012, the Russian Association for Osteoporosis initiated the PROMETHEUS project (abbreviation of Russian expression ‘creation of services for secondary fractures prevention in patients with osteoporosis’) aimed to improve the prevention of secondary fractures. AIM: To analyze the incidence rate of previous osteoporotic fractures in patients aged 50 years and older enrolled in the Secondary Fracture Prevention Service (SFPS) evaluate their risk factors, identify if these patients had been previously diagnosed with osteoporosis and received anti-osteoporotic treatment. METHODS: A continuous, cross-sectional, multicenter, observational case-control study was conducted. The study group consisted of patients with a history of any fragility fractures (apart from the ‘index’ fracture). The control group included patients who did not report any previous fractures. Risk factors, diagnosis, and anti-osteoporotic therapy were analyzed. RESULTS: During the study period, 991 patients were enrolled in the registry. Of these, 443 (44.7%) had a history of fragility fractures. The number of previous fractures per patient ranged from 1 to 11, with 273 (61.62%) patients having one previous fracture and 103 (23.25%) having two. Risk factors for fracture include disability (OR 1.67, 95% CI 1.22–2.30), thyrotoxicosis (OR 2.90, 95% CI 1.12–7.47), and chronic obstructive pulmonary disease (OR 2.81, 95% CI 1.00–7.95). CONCLUSION: Almost half of the patients included in SFPS had a history of previous fragility fractures. However, the frequency of diagnosing osteoporosis after the previous fracture and use of anti-osteoporotic drugs were quite low, which necessitates further improvements of medical care for elderly patients with osteoporotic fractures, as well as the wide introduction of SFPS, its integration in the primary care setting, and inclusion in educational programs for traumatologists and primary care physicians.
- 31 March 2026
- Published by Ryazan State Medical University in Nauka Molodykh (Eruditio Juvenium)
- Vol. 14 (1)
Characteristics of Patients with Secondary Osteoporotic Fractures: Risk Factors, Diagnosis, and Treatment According to PROMETHEUS Registry Data
BACKGROUND: Individuals who have suffered fragility fractures, deserve special attention. Diagnosis and treatment of such patients remain unsatisfactory. To address this issue, in 2012, the Russian Association for Osteoporosis initiated the PROMETHEUS project (abbreviation of Russian expression ‘creation of services for secondary fractures prevention in patients with osteoporosis’) aimed to improve the prevention of secondary fractures. AIM: To analyze the incidence rate of previous osteoporotic fractures in patients aged 50 years and older enrolled in the Secondary Fracture Prevention Service (SFPS) evaluate their risk factors, identify if these patients had been previously diagnosed with osteoporosis and received anti-osteoporotic treatment. METHODS: A continuous, cross-sectional, multicenter, observational case-control study was conducted. The study group consisted of patients with a history of any fragility fractures (apart from the ‘index’ fracture). The control group included patients who did not report any previous fractures. Risk factors, diagnosis, and anti-osteoporotic therapy were analyzed. RESULTS: During the study period, 991 patients were enrolled in the registry. Of these, 443 (44.7%) had a history of fragility fractures. The number of previous fractures per patient ranged from 1 to 11, with 273 (61.62%) patients having one previous fracture and 103 (23.25%) having two. Risk factors for fracture include disability (OR 1.67, 95% CI 1.22–2.30), thyrotoxicosis (OR 2.90, 95% CI 1.12–7.47), and chronic obstructive pulmonary disease (OR 2.81, 95% CI 1.00–7.95). CONCLUSION: Almost half of the patients included in SFPS had a history of previous fragility fractures. However, the frequency of diagnosing osteoporosis after the previous fracture and use of anti-osteoporotic drugs were quite low, which necessitates further improvements of medical care for elderly patients with osteoporotic fractures, as well as the wide introduction of SFPS, its integration in the primary care setting, and inclusion in educational programs for traumatologists and primary care physicians.
- 29 September 2025
- Published by ECO-Vector LLC in HERALD of North-Western State Medical University named after I.I. Mechnikov
- Vol. 17 (3) , 70-77
Medical and social consequences of osteoporotic proximal femoral fracture in residents of Yekaterinburg
BACKGROUND: The most severe complication of osteoporosis is a fracture of the proximal femur. High mortality, disability, and economic costs determine the significance of fractures at this site for healthcare. Repeat fractures following a proximal femoral fracture, associated with low levels of osteoporosis diagnosis and treatment, play a significant role in adverse outcomes. AIM: To assess the medical and social consequences of osteoporotic proximal femoral fractures and the frequency of secondary fractures, as well as the rate of osteoporosis detection and treatment in individuals at high risk of fractures, in order to inform subsequent changes in healthcare delivery approaches for this patient category. METHODS: A retrospective cohort study was conducted of patients aged 50 years and older, hospitalized at the Traumatology Department of Yekaterinburg Central City Clinical Hospital No. 23 during 2021 with a diagnosis of “proximal femoral fracture.” The study was performed in two stages. The first stage involved assessing surgical activity and in-hospital mortality in patients with osteoporotic proximal femoral fractures over a 12-month period. The second stage consisted of assessing the medical and social consequences, the detection and treatment of osteoporosis, and the frequency of repeat osteoporotic fractures one year after the proximal femoral fracture. RESULTS: The study included 514 patients with osteoporotic proximal femoral fractures. Of these, 72 (14%) individuals were transferred to hospitals repurposed for the treatment of the novel coronavirus infection. Surgical treatment was performed on 396 (89.6%) patients: arthroplasty — 157 (39.6%), osteosynthesis — 239 (60.4%). One year after the proximal femoral fracture, 351 (75.3%) were alive, and 115 (24.7%) had died. Medical and social consequences of the proximal femoral fracture were known for 178 individuals. Of these, 5.6% of patients remained immobilized, 53.4% had their activity limited to their apartment, and 41% had resumed an active lifestyle. Repeat fractures within one year occurred in 15.7% of patients. Only 10 (5.6%) individuals were taking anti-osteoporotic medication. CONCLUSION: The assessment of medical care for osteoporotic proximal femoral fractures showed satisfactory surgical activity, which led to a reduction in mortality after fractures at this site, but also revealed delayed timing of surgical treatment. Insufficient attention to osteoporosis as a cause of fractures and the rare prescription of anti-osteoporotic drugs were identified, indicating the necessity of implementing a system for the prevention of repeat fractures.
- 29 September 2025
- Published by ECO-Vector LLC in HERALD of North-Western State Medical University named after I.I. Mechnikov
- Vol. 17 (3) , 70-77
Medical and social consequences of osteoporotic proximal femoral fracture in residents of Yekaterinburg
BACKGROUND: The most severe complication of osteoporosis is a fracture of the proximal femur. High mortality, disability, and economic costs determine the significance of fractures at this site for healthcare. Repeat fractures following a proximal femoral fracture, associated with low levels of osteoporosis diagnosis and treatment, play a significant role in adverse outcomes. AIM: To assess the medical and social consequences of osteoporotic proximal femoral fractures and the frequency of secondary fractures, as well as the rate of osteoporosis detection and treatment in individuals at high risk of fractures, in order to inform subsequent changes in healthcare delivery approaches for this patient category. METHODS: A retrospective cohort study was conducted of patients aged 50 years and older, hospitalized at the Traumatology Department of Yekaterinburg Central City Clinical Hospital No. 23 during 2021 with a diagnosis of “proximal femoral fracture.” The study was performed in two stages. The first stage involved assessing surgical activity and in-hospital mortality in patients with osteoporotic proximal femoral fractures over a 12-month period. The second stage consisted of assessing the medical and social consequences, the detection and treatment of osteoporosis, and the frequency of repeat osteoporotic fractures one year after the proximal femoral fracture. RESULTS: The study included 514 patients with osteoporotic proximal femoral fractures. Of these, 72 (14%) individuals were transferred to hospitals repurposed for the treatment of the novel coronavirus infection. Surgical treatment was performed on 396 (89.6%) patients: arthroplasty — 157 (39.6%), osteosynthesis — 239 (60.4%). One year after the proximal femoral fracture, 351 (75.3%) were alive, and 115 (24.7%) had died. Medical and social consequences of the proximal femoral fracture were known for 178 individuals. Of these, 5.6% of patients remained immobilized, 53.4% had their activity limited to their apartment, and 41% had resumed an active lifestyle. Repeat fractures within one year occurred in 15.7% of patients. Only 10 (5.6%) individuals were taking anti-osteoporotic medication. CONCLUSION: The assessment of medical care for osteoporotic proximal femoral fractures showed satisfactory surgical activity, which led to a reduction in mortality after fractures at this site, but also revealed delayed timing of surgical treatment. Insufficient attention to osteoporosis as a cause of fractures and the rare prescription of anti-osteoporotic drugs were identified, indicating the necessity of implementing a system for the prevention of repeat fractures.
- Open Access
- 22 April 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (2) , 58-62
On the application of the “treat-to-target” strategy and the identification of a cohort of difficult-to-treat patients with rheumatoid arthritis in real-world clinical practice
Rheumatoid arthritis (RA) is an incurable but potentially controllable disease. The main goal of treatment is to achieve remission or low disease activity. Among difficult-to-treat patients, three groups are distinguished: patients whose treatment does not comply with the principle of “treat to target” (T2T) due to insufficient activity of the doctor, or due to non-compliance with the treatment regimen by the patient; cases where the central mechanisms of pain are not recognized; patients with “truly refractory RA.”Objective: to evaluate the implementation of the T2T strategy in the real-world clinical practice of rheumatologists, and the physicians' understanding of the mechanisms of the development of a difficult-to-treat RA.Material and methods. The study included three stages: 1) assessment of the duration of counting of DAS-28 index by doctors; 2) anonymous online survey of 43 rheumatologists from Yekaterinburg and the Sverdlovsk region; 3) assessment of patients' comprehension of the indicator “General activity of the disease”. The results of the study are presented in the form of descriptive statistics.Results and discussion. The average counting time of the DAS28 is 1 min 16 s, but only 42% of rheumatologists calculated it correctly. The problem of physicians' insufficient attention to the subjective component of the DAS28 index and possible central sensitization as a cause of pain was revealed. Assessment of health is difficult and ambiguous for the patients.Conclusion. The implementation of the T2T strategy in the treatment of patients with RA cannot be considered optimal today. Often the DAS28 index is used in a purely mechanical way without considering central sensitization, which can lead to overdiagnosis of the high inflammatory activity of RA as well as to unjustified changes in therapy.
- 22 April 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (2) , 58-62
Open AccessOn the application of the “treat-to-target” strategy and the identification of a cohort of difficult-to-treat patients with rheumatoid arthritis in real-world clinical practice
Rheumatoid arthritis (RA) is an incurable but potentially controllable disease. The main goal of treatment is to achieve remission or low disease activity. Among difficult-to-treat patients, three groups are distinguished: patients whose treatment does not comply with the principle of “treat to target” (T2T) due to insufficient activity of the doctor, or due to non-compliance with the treatment regimen by the patient; cases where the central mechanisms of pain are not recognized; patients with “truly refractory RA.”Objective: to evaluate the implementation of the T2T strategy in the real-world clinical practice of rheumatologists, and the physicians' understanding of the mechanisms of the development of a difficult-to-treat RA.Material and methods. The study included three stages: 1) assessment of the duration of counting of DAS-28 index by doctors; 2) anonymous online survey of 43 rheumatologists from Yekaterinburg and the Sverdlovsk region; 3) assessment of patients' comprehension of the indicator “General activity of the disease”. The results of the study are presented in the form of descriptive statistics.Results and discussion. The average counting time of the DAS28 is 1 min 16 s, but only 42% of rheumatologists calculated it correctly. The problem of physicians' insufficient attention to the subjective component of the DAS28 index and possible central sensitization as a cause of pain was revealed. Assessment of health is difficult and ambiguous for the patients.Conclusion. The implementation of the T2T strategy in the treatment of patients with RA cannot be considered optimal today. Often the DAS28 index is used in a purely mechanical way without considering central sensitization, which can lead to overdiagnosis of the high inflammatory activity of RA as well as to unjustified changes in therapy.
- Open Access
- 14 June 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (3) , 32-43
Efficacy and safety of levilimab in the treatment of rheumatoid arthritis in real-life clinical practice: first results of the HELIOS observational study
The efficacy and safety of levilimab (LVL) in patients with active rheumatoid arthritis (RA) has been confirmed in controlled clinical trials. This article presents the results of a preliminary analysis of a non-interventional observational study of LVL in RA patients. Objective: to evaluate the efficacy and safety of LVL in the treatment of patients with RA in real-world clinical practice. Materials and methods. The HELIOS study is a retrospective-prospective, multicenter, non-interventional study of retention rate of LVL therapy and the safety of LVL in patients with RA in real-world clinical practice. Patients received medical care, including LVL, according to routine clinical practice for the treatment of RA and Russian instructions for medical use of the drug. This article presents the results of an analysis of the efficacy and safety of LVL after 12 and 24 weeks of treatment. Efficacy was assessed using the DAS28-CRP/ESR, SDAI, CDAI and patient assessment of pain, fatigue and morning stiffness according to VAS (0–100 mm). Results and discussion. 524 patients from 42 medical centers in the Russian Federation were enrolled in the study from June 2022 to November 2023. The majority of patients were female (83.2 %) and the mean age of patients was 53 years. A statistically significant decrease in DAS28-CRP/ESR, SDAI, CDAI, patient assessment of pain, fatigue and morning stiffness (VAS) was observed after 12 and 24 weeks of treatment, regardless of previous treatment with biologics or Jak inhibitors (JAKi). LVL was well tolerated by patients, the most frequently reported adverse events were infections, changes in peripheral blood and laboratory abnormalities characteristic of treatment with IL-6R inhibitors. Conclusion. In real-world clinical practice, LVL has been shown to be highly effective and well tolerated in patients with RA when prescribed as the first biologic disease-modifying antirheaumatic drus (bDMARD) and after switching from other bDMARDs or JAKi.
- 14 June 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (3) , 32-43
Open AccessEfficacy and safety of levilimab in the treatment of rheumatoid arthritis in real-life clinical practice: first results of the HELIOS observational study
The efficacy and safety of levilimab (LVL) in patients with active rheumatoid arthritis (RA) has been confirmed in controlled clinical trials. This article presents the results of a preliminary analysis of a non-interventional observational study of LVL in RA patients. Objective: to evaluate the efficacy and safety of LVL in the treatment of patients with RA in real-world clinical practice. Materials and methods. The HELIOS study is a retrospective-prospective, multicenter, non-interventional study of retention rate of LVL therapy and the safety of LVL in patients with RA in real-world clinical practice. Patients received medical care, including LVL, according to routine clinical practice for the treatment of RA and Russian instructions for medical use of the drug. This article presents the results of an analysis of the efficacy and safety of LVL after 12 and 24 weeks of treatment. Efficacy was assessed using the DAS28-CRP/ESR, SDAI, CDAI and patient assessment of pain, fatigue and morning stiffness according to VAS (0–100 mm). Results and discussion. 524 patients from 42 medical centers in the Russian Federation were enrolled in the study from June 2022 to November 2023. The majority of patients were female (83.2 %) and the mean age of patients was 53 years. A statistically significant decrease in DAS28-CRP/ESR, SDAI, CDAI, patient assessment of pain, fatigue and morning stiffness (VAS) was observed after 12 and 24 weeks of treatment, regardless of previous treatment with biologics or Jak inhibitors (JAKi). LVL was well tolerated by patients, the most frequently reported adverse events were infections, changes in peripheral blood and laboratory abnormalities characteristic of treatment with IL-6R inhibitors. Conclusion. In real-world clinical practice, LVL has been shown to be highly effective and well tolerated in patients with RA when prescribed as the first biologic disease-modifying antirheaumatic drus (bDMARD) and after switching from other bDMARDs or JAKi.
- 23 April 2024
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 27 (8)
Organization of a Secondary Fracture Prevention System. Expert group recommendations
Preventing fractures in older people is a strategic task of modern Russian healthcare, which aims to maintain the citizens’ quality of life and reduce costs related to fractures. A Secondary Fracture Prevention System (SFPS) is the most efficient and cost-effective organizational structure for reducing the frequency of fractures. The main purpose of SFPS is to ensure interaction between traumatological, therapeutic, and geriatric services and involve PHC specialists in reducing the frequency of recurrent fractures in all older and senile patients after low-energy fractures. The article covers the main principles of establishing a regional- or organizational-level SFPS.
- 23 April 2024
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 27 (8)
Organization of a Secondary Fracture Prevention System. Expert group recommendations
Preventing fractures in older people is a strategic task of modern Russian healthcare, which aims to maintain the citizens’ quality of life and reduce costs related to fractures. A Secondary Fracture Prevention System (SFPS) is the most efficient and cost-effective organizational structure for reducing the frequency of fractures. The main purpose of SFPS is to ensure interaction between traumatological, therapeutic, and geriatric services and involve PHC specialists in reducing the frequency of recurrent fractures in all older and senile patients after low-energy fractures. The article covers the main principles of establishing a regional- or organizational-level SFPS.
- Open Access
- 17 April 2024
- Published by Endocrinology Research Centre in Osteoporosis and Bone Diseases
- Vol. 27 (1) , 4-9
The consensus of experts of the russian association for osteoporosis on the long-term treatment of osteoporosis with bisphosphonates
Bisphosphonates are the most commonly used drugs for the treatment of osteoporosis and reducing the risk of fractures, which were introduced into clinical practice more than 30 years ago. The bisphosphonate group includes oral (alendronic acid, risedronic acid, ibandronic acid) and parenteral (zoledronic acid, ibandronic acid) preparations. By now, quite large groups of patients with osteoporosis have been taking bisphosphonates for a long time. This fact raises questions about the preservation of the clinical effect, the development of side effects of drugs against the background of prolonged administration, as well as the possibility of cessation or interruption in their use. The document contains recommendations of the experts of the Russian Association for Osteoporosis on the management of patients with osteoporosis receiving bisphosphonate therapy based on the literature review and discussion. The recommended duration of treatment with oral and parenteral bisphosphonates, methods for monitoring the effectiveness of treatment, as well as signs that should be used when deciding on a discontinuation of the therapy or an increase in its duration are formulated. The criteria of ineffectiveness of treatment requiring its correction are discussed. A separate section is devoted to monitoring the patient during a ‘drug holiday’ in taking bisphosphonates and making a decision on resuming treatment. Recommendations are also given for the control and prevention of possible side effects and increasing persistence to bisphosphonate treatment.
- 17 April 2024
- Published by Endocrinology Research Centre in Osteoporosis and Bone Diseases
- Vol. 27 (1) , 4-9
Open AccessThe consensus of experts of the russian association for osteoporosis on the long-term treatment of osteoporosis with bisphosphonates
Bisphosphonates are the most commonly used drugs for the treatment of osteoporosis and reducing the risk of fractures, which were introduced into clinical practice more than 30 years ago. The bisphosphonate group includes oral (alendronic acid, risedronic acid, ibandronic acid) and parenteral (zoledronic acid, ibandronic acid) preparations. By now, quite large groups of patients with osteoporosis have been taking bisphosphonates for a long time. This fact raises questions about the preservation of the clinical effect, the development of side effects of drugs against the background of prolonged administration, as well as the possibility of cessation or interruption in their use. The document contains recommendations of the experts of the Russian Association for Osteoporosis on the management of patients with osteoporosis receiving bisphosphonate therapy based on the literature review and discussion. The recommended duration of treatment with oral and parenteral bisphosphonates, methods for monitoring the effectiveness of treatment, as well as signs that should be used when deciding on a discontinuation of the therapy or an increase in its duration are formulated. The criteria of ineffectiveness of treatment requiring its correction are discussed. A separate section is devoted to monitoring the patient during a ‘drug holiday’ in taking bisphosphonates and making a decision on resuming treatment. Recommendations are also given for the control and prevention of possible side effects and increasing persistence to bisphosphonate treatment.
- Open Access
- 17 April 2024
- Published by Endocrinology Research Centre in Osteoporosis and Bone Diseases
- Vol. 26 (4) , 8-13
Review of recommendations for bisphosphonate treatment interruption-discontinuation
Bisphosphonates are the main medications in the treatment of osteoporosis, which are effective in reducing the risk of fractures in patients with osteoporosis. It is known that after treatment with bisphosphonates, bone mineral density remains quite stable for a certain time, as well as markers of bone metabolism remain reduced, which, along with the side effects of long-term bisphosphonate therapy, determines the possibility of “Drug holidays”. At the same time, during a break in bisphosphonate treatment, the risk of fractures begins to increase, which is a reason to resume therapy.Currently, there is no uniform worldwide data of starting a “drug holidays” on bisphosphonates. The duration of the “drug holidays” also differs in clinical recommendations from different countries. When to conduct a risk assessment of fractures during a “drug holidays”? To answer these questions, we assessed existing clinical recommendations for treatment interruption/discontinuation of bisphosphonates. A literature search was conducted using the following resources: PubMed®, the Cochrane Library, websites of major international osteoporosis associations, and other targeted Internet searches. The main search terms were “Clinical Guideline of Osteoporosis”, “Bisphosphonates”, “Drug holidays in osteoporosis”, “Discontinuation of bisphosphonates”. Тhe search was carried out using articles in Russian and English published between January 1, 2016 and September 15, 2023. 17 clinical guidelines from different countries (Russian, American, European, Asian and Australian) were found and analyzed in which was information about the break in the treatment and withdrawal of bisphosphonates.The majority of clinical recommendations have the same opinion on the issue of starting “drug holidays”: with a moderate risk of fractures, you can take a break from treatment with tableted bisphosphonates after 5 years, after zoledronic acid — after 3 years of therapy. At high and very high risk of fractures, the duration of treatment is 10 and 6 years, respectively. The duration of “drug holidays” vary in the recommendations, but in most cases the decision-making is based not on the duration, but on the assessment of the risk of fractures with their regular reassessment, which includes previous and new low-energy fractures, the emergence of new risk factors, a decrease in BMD, the dynamics of bone markers, re-evaluation of FRAX®.
- 17 April 2024
- Published by Endocrinology Research Centre in Osteoporosis and Bone Diseases
- Vol. 26 (4) , 8-13
Open AccessReview of recommendations for bisphosphonate treatment interruption-discontinuation
Bisphosphonates are the main medications in the treatment of osteoporosis, which are effective in reducing the risk of fractures in patients with osteoporosis. It is known that after treatment with bisphosphonates, bone mineral density remains quite stable for a certain time, as well as markers of bone metabolism remain reduced, which, along with the side effects of long-term bisphosphonate therapy, determines the possibility of “Drug holidays”. At the same time, during a break in bisphosphonate treatment, the risk of fractures begins to increase, which is a reason to resume therapy.Currently, there is no uniform worldwide data of starting a “drug holidays” on bisphosphonates. The duration of the “drug holidays” also differs in clinical recommendations from different countries. When to conduct a risk assessment of fractures during a “drug holidays”? To answer these questions, we assessed existing clinical recommendations for treatment interruption/discontinuation of bisphosphonates. A literature search was conducted using the following resources: PubMed®, the Cochrane Library, websites of major international osteoporosis associations, and other targeted Internet searches. The main search terms were “Clinical Guideline of Osteoporosis”, “Bisphosphonates”, “Drug holidays in osteoporosis”, “Discontinuation of bisphosphonates”. Тhe search was carried out using articles in Russian and English published between January 1, 2016 and September 15, 2023. 17 clinical guidelines from different countries (Russian, American, European, Asian and Australian) were found and analyzed in which was information about the break in the treatment and withdrawal of bisphosphonates.The majority of clinical recommendations have the same opinion on the issue of starting “drug holidays”: with a moderate risk of fractures, you can take a break from treatment with tableted bisphosphonates after 5 years, after zoledronic acid — after 3 years of therapy. At high and very high risk of fractures, the duration of treatment is 10 and 6 years, respectively. The duration of “drug holidays” vary in the recommendations, but in most cases the decision-making is based not on the duration, but on the assessment of the risk of fractures with their regular reassessment, which includes previous and new low-energy fractures, the emergence of new risk factors, a decrease in BMD, the dynamics of bone markers, re-evaluation of FRAX®.
- Open Access
- 28 June 2023
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 61 (3) , 320-329
FRAX-based intervention thresholds for men in the Russian Federation: Expert consensus of the Russian association on osteoporosis
According to the European guidelines for osteoporosis, the same FRAX intervention threshold is suggested for men as for women. At the same time, in the Russian Federation, according to research data, an extremely low proportion of identified men who are subject to the initiation of osteoporosis therapy. The female intervention threshold identifies only 1.1 to 4% of men for treatment. Aim – to develop and evaluate various options for the intervention threshold using the FRAX calculator for men in the Russian Federation and adopt the most acceptable intervention threshold by consensus. Material and methods. Delphi voting was conducted among 18 Russian experts who have publications and personal reports about their experience with the FRAX calculator. For discussion, 5 intervention threshold options with the corresponding rationale based on the literature reference were presented, as well as the proportion of men of different ages to be initiated in each of the options (based on several Russian population-based studies). Anonymous voting was carried out using the Delphi method with questionnaire placed in the Google form. It was proposed to evaluate all options for intervention thresholds on a 9-point Likert scale. Consensus was considered reached if the intervention threshold reached a Likert score of 7 or more points in 80% or more of the experts. The rating of each intervention threshold option was expressed as mean and standard deviations. Results. In the first round of voting, the maximum rating and percentage of agreement is reached for the 9% fixed interference threshold option based on the FRAX calculation. The rating was 7.72±1.6 points, the percentage of experts’ agreement was 88.9%. A fixed threshold of 9% determined 13–19.5% of men aged 50 years and older to be treated for osteoporosis, while their proportion increased to 26–38% at the age of 85 years and older. Conclusion. The consensus of experts of the Russian association on osteoporosis suggests initiating treatment of osteoporosis in Russian men with a 10-year probability of major osteoporotic fractures according to FRAX of 9% or higher.
- 28 June 2023
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 61 (3) , 320-329
Open AccessFRAX-based intervention thresholds for men in the Russian Federation: Expert consensus of the Russian association on osteoporosis
According to the European guidelines for osteoporosis, the same FRAX intervention threshold is suggested for men as for women. At the same time, in the Russian Federation, according to research data, an extremely low proportion of identified men who are subject to the initiation of osteoporosis therapy. The female intervention threshold identifies only 1.1 to 4% of men for treatment. Aim – to develop and evaluate various options for the intervention threshold using the FRAX calculator for men in the Russian Federation and adopt the most acceptable intervention threshold by consensus. Material and methods. Delphi voting was conducted among 18 Russian experts who have publications and personal reports about their experience with the FRAX calculator. For discussion, 5 intervention threshold options with the corresponding rationale based on the literature reference were presented, as well as the proportion of men of different ages to be initiated in each of the options (based on several Russian population-based studies). Anonymous voting was carried out using the Delphi method with questionnaire placed in the Google form. It was proposed to evaluate all options for intervention thresholds on a 9-point Likert scale. Consensus was considered reached if the intervention threshold reached a Likert score of 7 or more points in 80% or more of the experts. The rating of each intervention threshold option was expressed as mean and standard deviations. Results. In the first round of voting, the maximum rating and percentage of agreement is reached for the 9% fixed interference threshold option based on the FRAX calculation. The rating was 7.72±1.6 points, the percentage of experts’ agreement was 88.9%. A fixed threshold of 9% determined 13–19.5% of men aged 50 years and older to be treated for osteoporosis, while their proportion increased to 26–38% at the age of 85 years and older. Conclusion. The consensus of experts of the Russian association on osteoporosis suggests initiating treatment of osteoporosis in Russian men with a 10-year probability of major osteoporotic fractures according to FRAX of 9% or higher.